Indonesia Hepatitis C Drugs Market Analysis

Indonesia Hepatitis C Drugs Market Analysis


$ 3999

Indonesia Hepatitis C drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 – 2030. The market will grow as a result of a number of factors, including the expansion of the pharmaceutical sector, an ageing population, growing healthcare expenditures, urbanisation, better monitoring and screening technologies, and a rise in liver cancer and cirrhosis fatalities brought on by HBV. Some of the major key players in this market are Bristol-Myers Squibb Company Gilead Sciences, Inc. Abbvie Kadmon Holdings Inc. F. Hoffmon La Roche Ltd. GlaxoSmithKline J & J Lupin Pharmaceuticals, Inc. Merck & Co., Inc. Teva Pharmaceuticals and Zydus Pharmaceuticals.

ID: IN10IDPH299 CATEGORY: Pharmaceuticals GEOGRAPHY: Indonesia AUTHOR: Dr. Medha Sansanwal

Buy Now

Indonesia Hepatitis C Drugs Market Analysis Summary

Indonesia Hepatitis C Drugs Market is valued at around $136.1 Mn in 2022 and is projected to reach $422.1 Mn by 2030, exhibiting a CAGR of 15.2% during the forecast period 2023-2030.

Hepatitis C, a viral condition, causes the liver to become inflamed, which can cause serious liver damage. The hepatitis C virus can spread through contaminated blood (HCV). A lot of HCV-infected people found it challenging to take the weekly injections and oral medications that were previously necessary for hepatitis C therapy because of underlying health conditions or unfavourable side effects. That is altering. Today, oral medicines used daily for two to six months can usually cure chronic HCV. The majority of HCV infected people don't exhibit any symptoms, which might take years to appear, thus they are unaware of their infection, which leaves about half of individuals. Even those without symptoms or a history of liver disease should get tested for hepatitis C, according to the U.S. Preventive Services Task Force. The market will grow as a result of a number of factors, including the expansion of the pharmaceutical sector, an ageing population, growing healthcare expenditures, urbanisation, better monitoring and screening technologies, and a rise in liver cancer and cirrhosis fatalities brought on by HBV. The global Hepatitis C Drugs market’s major key players are Bristol-Myers Squibb Company Gilead Sciences, Inc. Abbvie Kadmon Holdings Inc. F. Hoffmon La Roche Ltd. GlaxoSmithKline J & J Lupin Pharmaceuticals, Inc. Merck & Co., Inc. Teva Pharmaceuticals and Zydus Pharmaceuticals.

Market Dynamics

Market Growth Drivers

  1. Increased awareness and the creation of new drugs are anticipated to drive the market for treating Hepatitis C
  2. The ability of medications to treat hepatitis C will increase demand worldwide
  3. rising new drug approvals and new drug releases for hepatitis
  4. Hepatitis C virus is becoming more common

Market Restraints

The market for hepatitis pharmaceuticals is forecast to increase slowly over the anticipated period because of the high capital required for hepatitis pharmaceutical production. The cost of hepatitis therapies is high. Hepatitis drugs are pricey because they are created from high-priced fundamental components including active pharmaceutical ingredients (APIs) and pharmacological intermediates. The complex procedure of generating, sorting, and utilising raw materials for the development of pharmaceutical and biopharmaceutical treatments increases the cost of pharmaceuticals as expert labour is required.

Competitive Landscape

Key Players

  • Gilead Sciences
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Vertex Pharmaceuticals
  • Roche Holding AG
  • Novartis International AG
  • Eli Lilly and Company
  • AstraZeneca PLC

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Indonesia Hepatitis C Drugs Market Segmentation

By Disease Type

  • Acute hepatitis C
  • Chronic hepatitis C

By Channel Type

  • Direct Sales
  • Distributor

By Product Type

  • Protease inhibitors
  • Fixed dose combinations
  • others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Ritu Baliya

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up